Abstract 1163P
Background
PRRT with 177Lu-Dotatate (Lutathera®) (LU) offers an effective approach in gastroenteropancreatic NETs. We know that systemic inflammatory (SI) parameters could show poorer results, however, it remains unknown in patients (p) treated with PRRT. We aim to analyze the prognostic value of SI biomarkers in NETs undergoing LU.
Methods
Retrospective and multicentric study of NETs receiving LU between 2016 and 2024. Clinical features and blood test [at baseline (BL) and after two cycles of PRRT] data were collected to determine SI markers and calculate the following ratios: neutrophil to lymphocyte (NLR), monocyte to lymphocyte (MLR), platelet to lymphocyte (PLR) and albumin to lymphocyte (ALR). The cut-off values were determined as the median of each variable, correlating them with progression-free (PFS) and overall survival (OS).
Results
44 patients (p) with NETs were included with a median age of 57 years and 54.5% males. NETs were of gastrointestinal (n=16), pancreatic (n=15), pulmonary (n=7) and unknown (n=6) origin. Tumor grade (G) was G1 (29.5%) and G2/3 (70.5%). 25p (56.8%) received ≥2 lines of treatment prior to PRRT. We observed significant poorer PFS in p with pulmonary vs pancreatic NETs (16.3m vs 27.7m; p=0.02), and a trend inhigher tumor G (23.6m vs 36.5m; p=0.26) and with ≥2 metastatic sites (23.6m vs 36.5m; p=0.58). We identified as BL values of good prognosis lower ratios of NLR, MLR, PLR and ALR. Also, BL SII (as a set of the parameters analyzed) showed a favorable trend with a score ≤2 in PFS (34.7m vs 12.8m, p=0.07) and in OS (NR vs 29.6m; p=0.09). After2 cycles of LU, SII score ≤2 significantly predicted better OS (NR vs 12.6m; p=0.02).
Table: 1163P
Prognostic value of inflammatory biomarkers in patients with neuroendocrine tumors treated with PRRT
PFS median (months) | Log-rank p-value | OS median (months) | Log-rank p-value | ||
BL NLR | ConclusionsA SII score ≤2 at baseline or at reassessment could predict better oncological outcomes, although prospective validation is required. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureD. Morchón Araujo: Financial Interests, Personal, Invited Speaker: Astellas Pharma, PharmaMar. R. Lozano Mejorada: Financial Interests, Personal, Invited Speaker: Janssen, Astellas, Roche, Bayer, Ipsen, AstraZeneca; Financial Interests, Personal, Advisory Board: Janssen, Merck, Pfizer, Orion Pharma, Advanced Accelerator Applications (Novartis); Financial Interests, Personal, Other, Travel/accommodation: MSD, Sanofi; Financial Interests, Personal, Other, Travel/accommodation: BMS; Non-Financial Interests, Member: Sociedad Española de Oncología Médica. All other authors have declared no conflicts of interest. Resources from the same session1427P - Predicting overall survival and prognostic indicator genes in esophagogastric cancer patients using machine learning and bioinformatics analysisPresenter: Nguyen-Kieu Viet-Nhi Session: Poster session 17 1428P - Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort studyPresenter: Hollie Clements Session: Poster session 17 1429P - Differences in esophageal cancer incidence and survival by race/ethnicity: A SEER analysisPresenter: Ashwin Kulshrestha Session: Poster session 17 1430P - Impact of menadione supplementation in the treatment of patients with metastatic gastric cancer: A randomized phase II clinical trialPresenter: Francisco Cezar Moraes Session: Poster session 17 1431P - Assessing pathological complete response to neoadjuvant chemotherapy combined with immunotherapy in esophageal squamous cell carcinoma: A deep learning approach with voxel-level radiomicsPresenter: Yongling Ji Session: Poster session 17 1432P - Safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: A prospective multicenter trial (CLASS-03a)Presenter: Kun Yang Session: Poster session 17 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|